Penetrium Bioscience
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Penetrium Bioscience manages clinical trials on behalf of pharmaceutical companies and biotech ventures, handling the complex, multi-phase testing process that a new drug or medical device must complete before it can reach patients.
It provides end-to-end services covering trial design, patient recruitment, data management, regulatory submissions, and drug-safety monitoring, and it also conducts post-approval studies that track a product's long-term safety and effectiveness in real-world use. The company is listed on KOSDAQ, South Korea's technology and small-cap exchange.
Summary is AI-generated and may contain errors · figures from DART filings
Penetrium Bioscience in five facts
What does Penetrium Bioscience do?
Penetrium Bioscience manages clinical trials on behalf of pharmaceutical companies and biotech ventures, handling the complex, multi-phase testing process that a new drug or medical device must complete before it can reach patients.
Where is Penetrium Bioscience listed and in which sector?
Penetrium Bioscience (Korean name: 페니트리움바이오) trades under KRX code 187660 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Biotechnology.
How large is Penetrium Bioscience?
Its market capitalisation was US$276.2M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Penetrium Bioscience's latest annual revenue and operating profit?
For fiscal year 2025, Penetrium Bioscience reported revenue of US$7M, an operating loss of US$5.6M and a net loss of US$11.2M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was down 4.8% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on securities held by executives/major shareholdersOct 19
- Report on large shareholdings (5% rule) (standard)Oct 14
- Report on large shareholdings (5% rule) (standard)Sep 9
- [Amended] Report on large shareholdings (5% rule) (standard)Sep 9
- Report on large shareholdings (5% rule) (standard)Sep 4
- Report on securities held by executives/major shareholdersSep 4
- Material management matter relevant to investment decisionsSep 3
- Report on securities held by executives/major shareholdersSep 2
- [Amended] Subscription results of rights offering or equity-linked bonds (voluntary)
Penetrium Bioscience amended its rights-offering subscription results to correct an erroneous subscription-rate figure for the general public offering tranche, from 419.03% to 41,903.31%.
Capital raise · Aug 12 · 2 versions - Subscription results of rights offering or equity-linked bonds (voluntary)
Penetrium Bioscience Co., Ltd. reports a 91.03% subscription rate (7,737,661 of 8,500,000 planned shares) in its shareholder-allocation rights offering closed August 6, 2026; the resulting 762,339 forfeited shares will be offered to the general public on August 10-11, 2026, with any remainder underwritten by lead manager Yuanta Securities.
Capital raise · Aug 7 - Rights offering: final issue price set
Penetrium Bioscience set the final issue price for its 8,500,000-share rights offering at US$2.16 per share (versus a round-1 price of US$2.84 and round-2 price of US$2.16), with a par value of US$0.07, as determined on 2026-07-31.
Capital raise · Aug 3 - [Amended] Material event report (rights offering)
Penetrium Bioscience updated the terms of a new share issuance to raise US$18.4M, about 6.0% of its market value.
Capital raise · Aug 3 · 5 versions - Ex-rights (rights offering)Capital raise · Jun 26
- Rights offering: round 1 issue price setCapital raise · Jun 26
- [Amended] Supply contract signedSupply contract · Mar 17
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)Earnings · Jan 22